Menu Search
Equities

Liquidia Corp

LQDA:NAQ

Liquidia Corp

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)10.65
  • Today's Change0.50 / 4.93%
  • Shares traded1.05m
  • 1 Year change+58.48%
  • Beta0.1910
Data delayed at least 15 minutes, as of Nov 22 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Liquidia Corp had net income fall 91.40% from a loss of 41.02m to a larger loss of 78.50m despite a 9.75% increase in revenues from 15.94m to 17.49m. An increase in the selling, general and administrative costs as a percentage of sales from 203.40% to 255.84% was a component in the falling net income despite rising revenues.
Gross margin64.65%
Net profit margin-765.37%
Operating margin-742.42%
Return on assets-65.55%
Return on equity-150.73%
Return on investment-75.02%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Liquidia Corp fell by 9.60m. Cash Flow from Financing totalled 43.25m or 247.30% of revenues. In addition the company used 41.56m for operations while cash used for investing totalled 11.29m.
Cash flow per share-1.60
Price/Cash flow per share--
Book value per share1.31
Tangible book value per share1.22
More ▼

Balance sheet in USDView more

Liquidia Corp appears to have a strong balance sheet with enough cash in the capital structure to pay down 100% of the liabilities.
Current ratio6.33
Quick ratio6.33
Total debt/total equity1.02
Total debt/total capital0.5059
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.